BioAge Labs, Inc. (BIOA)
| Market Cap | 255.07M -11.2% |
| Revenue (ttm) | 8.60M +45.3% |
| Net Income | -107.80M |
| EPS | -2.54 |
| Shares Out | 45.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 427,503 |
| Open | 5.87 |
| Previous Close | 5.65 |
| Day's Range | 5.39 - 5.87 |
| 52-Week Range | 4.81 - 25.96 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 28.89 (+420.54%) |
| Earnings Date | Nov 5, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for BIOA stock is "Buy." The 12-month stock price target is $28.89, which is an increase of 420.54% from the latest price.
News
BioAge Labs Transcript: Stifel 2026 Healthcare Conference 2026
Phase I showed deep, sustained NLRP3 inhibition with once-daily BGE-102. QUELL-CV data are expected by year-end and QUELL-DME top-line results by the end of next year; ASCVD remains paused pending decisive ARTEMIS data.
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
BioAge Labs Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
The human-aging platform supports NLRP3 and APJ programs, with QUELL-CV data expected soon and DME results in H2 next year. Cash of just over $350 million at the last update provides runway through 2029.
BioAge Labs price target lowered to $40 from $73 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on BioAge Labs (BIOA) to $40 from $73 and keeps an Overweight rating on the shares. Ziltivekimab’s Phase 3 ZEUS…
BioAge Labs reports Q3 EPS (73c), consensus (63c)
Reports Q3 revenue $298,000, consensus $1.48M. “NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6...
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
BioAge Labs Quarterly report: Q3 2026
BioAge Labs has published its Q3 2026 quarterly earnings report on November 5, 2026.
BioAge Labs Earnings release: Q3 2026
BioAge Labs released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Or...
BioAge Labs initiated with a Neutral at UBS
UBS analyst Alice Nettleton initiated coverage of BioAge Labs (BIOA) with a Neutral rating and $8 price target While the company’s lead asset BGE-102 would be a differentiated NLRP3 inhibitor,…
BioAge Labs Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
BGE-102, a novel NLRP3 inhibitor, is advancing through two phase II trials targeting cardiometabolic and ophthalmology indications, with strong early efficacy and safety data. Strategic collaborations, a robust platform, and a broad IP estate support pipeline growth, while the ASCVD program is paused pending external data.
BioAge Labs Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
BGE-102, a best-in-class NLRP3 inhibitor, is advancing in phase II trials for cardiovascular and retinal diseases, with key efficacy data expected next year. The pipeline also includes an apelin agonist nearing IND filing and strong strategic partnerships. Cash reserves support operations into 2029.
BioAge Labs Transcript: Citigroup’s Biopharma Back to School Summit 2026
BGE-102 advanced to two phase II trials, including DME, with strong biomarker and safety data. The oral therapy's unique profile targets unmet needs in ophthalmology and metabolic diseases, while robust financials and a data-driven pipeline support expansion into new indications.
BioAge Labs doses first patient in QUELL-DME study
BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema. Th...
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity a...
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on BioAge Labs (BIOA) to $20 from $23 and keeps an Equal Weight rating on the shares.
BioAge Labs price target lowered to $21 from $52 at Citi
Citi lowered the firm’s price target on BioAge Labs (BIOA) to $21 from $52 and keeps a Buy rating on the shares.
BioAge Labs reports Q2 EPS (58c), consensus (62c)
Reports Q2 revenue $2.45M, consensus $1.5M. “NLRP3 sits at the apex of the inflammatory cascade that drives a range of diseases,” said Kristen Fortney, CEO and co-founder of BioAge. “Our…
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
BioAge Labs Quarterly report: Q2 2026
BioAge Labs has published its Q2 2026 quarterly earnings report on August 5, 2026.
BioAge Labs Earnings release: Q2 2026
BioAge Labs released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BioAge Labs price target lowered to $25 from $36 at Roth Capital
Roth Capital analyst Adam Walsh lowered the firm’s price target on BioAge Labs (BIOA) to $25 from $36 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO)…
BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi
Citi notes that BioAge Labs (BIOA) shares are down greater than 60% following the news that Novo Nordisk’s (NVO) ZEUS trial for ziltivekimab failed to demonstrate a benefit on MACE.
BioAge Labs price target lowered at Jefferies after Novo trial miss
Jefferies lowered the firm’s price target on BioAge Labs (BIOA) to $21 from $62 and keeps a Buy rating on the shares, stating that the “outright MACE failure” of Novo…
BioAge Labs price target lowered to $50 from $60 at Oppenheimer
Oppenheimer lowered the firm’s price target on BioAge Labs (BIOA) to $50 from $60 and keeps an Outperform rating on the shares.